Dianthus Therapeutics, Inc. DNTH
88.81 USD -1.19 (-1.32%)
At closeNov 10, 2026, 7:53 PM EST
86.70 -2.11 -2.38%
After hours · Nov 10, 7:53 PM ET
86.92 Day range 90.48
34.29 52-week range 117.88
- YTD
- +115.51%
- 1 year
- +142.58%
News
zacks.com Wall Street Analysts See a 61.23% Upside in Dianthus Therapeutics, Inc. (DNTH): Can the Stock Really Move This High? The mean of analysts' price targets for Dianthus Therapeutics, Inc. (DNTH) points to a 61.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong…
zacks.com Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Beats Revenue Estimates Dianthus Therapeutics, Inc. (DNTH) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $1. This compares to a loss of $0.97 per share a year ago.
globenewswire.com Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 2026 Financial Results Advancing a neuromuscular franchise with claseprubart, a highly potent, investigational classical pathway inhibitor, with best-in-disease potential across generalized Myasthenia Gravis (gMG), Chronic…
globenewswire.com Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NEW YORK and WALTHAM, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to…
globenewswire.com Dianthus Therapeutics to Participate in Five Investor Conferences During November NEW YORK and WALTHAM, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to…
benzinga.com This PPL Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday Analysts initiated Buy coverage on DRIO ($6), WATT ($15), PPL ($41), DNTH ($113); PYPD rated Outperform with a $10 target.
benzinga.com Roth Capital Initiates Coverage On Dianthus Therapeutics with Buy Rating, Announces Price Target of $113 Roth Capital analyst Adam Walsh initiates coverage on Dianthus Therapeutics (NASDAQ:DNTH) with a Buy rating and announces Price Target of $113.
benzinga.com HC Wainwright & Co. Reiterates Buy on Dianthus Therapeutics, Maintains $158 Price Target HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Dianthus Therapeutics (NASDAQ:DNTH) with a Buy and maintains $158 price target.
globenewswire.com Dianthus Therapeutics Recognized Among Fortune's 2026 Best Workplaces In BioPharma NEW YORK and WALTHAM, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to…
benzinga.com Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Quarter Oversold health care stocks Align Technology, Dianthus Therapeutics and Ocular Therapeutix show RSI readings near or below 30, signaling potential value.
globenewswire.com Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NEW YORK and WALTHAM, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to…
globenewswire.com Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2026 AANEM Annual Meeting NEW YORK and WALTHAM, Mass., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to…
benzinga.com This Shopify Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday Wall Street analysts initiated coverage on PPG, Shopify, Chesapeake Utilities, Global Payments and Dianthus, with targets ranging from $101 to $160.
benzinga.com JP Morgan Initiates Coverage On Dianthus Therapeutics with Overweight Rating, Announces Price Target of $135 JP Morgan analyst Brian Cheng initiates coverage on Dianthus Therapeutics (NASDAQ:DNTH) with a Overweight rating and announces Price Target of $135.
seekingalpha.com Dianthus Therapeutics, Inc. (DNTH) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript Dianthus Therapeutics, Inc. (DNTH) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript- benzinga.com Citigroup Initiates Coverage On Dianthus Therapeutics with Buy Rating, Announces Price Target of $156 Citigroup analyst Samantha Semenkow initiates coverage on Dianthus Therapeutics (NASDAQ:DNTH) with a Buy rating and announces Price Target of $156.
globenewswire.com Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NEW YORK and WALTHAM, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to…
globenewswire.com Dianthus Therapeutics to Participate in Three Investor Conferences During September NEW YORK and WALTHAM, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to…
defenseworld.net Alyeska Investment Group L.P. Has $14.68 Million Stock Position in Dianthus Therapeutics, Inc. $DNTH Alyeska Investment Group L.P. increased its position in shares of Dianthus Therapeutics, Inc. (NASDAQ: DNTH) by 188.2% in the undefined quarter, according to the company in its most recent filing…
seekingalpha.com Dianthus Therapeutics: The C1s Shakeout Strengthens The Bull Case Dianthus Therapeutics is building a neuromuscular franchise around claseprubart, differentiated by clinical profile and financial independence. DNTH holds ~$1.2B in cash and investments, supporting…
globenewswire.com Agomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors Antwerp, Belgium, August 10, 2026 - Agomab Therapeutics NV (Nasdaq: AGMB) ("Agomab" or the "Company"), a clinical-stage biopharmaceutical company focused on fibro-inflammatory diseases, today…
defenseworld.net California State Teachers Retirement System Raises Stock Holdings in Dianthus Therapeutics, Inc. $DNTH California State Teachers Retirement System boosted its stake in shares of Dianthus Therapeutics, Inc. (NASDAQ: DNTH) by 155.5% in the undefined quarter, according to the company in its most recent…
benzinga.com Truist Securities Maintains Buy on Dianthus Therapeutics, Raises Price Target to $128 Truist Securities analyst Danielle Brill maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Buy and raises the price target from $110 to $128.
benzinga.com HC Wainwright & Co. Maintains Buy on Dianthus Therapeutics, Raises Price Target to $158 HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Buy and raises the price target from $130 to $158.
defenseworld.net Dimensional Fund Advisors LP Purchases 114,767 Shares of Dianthus Therapeutics, Inc. $DNTH Dimensional Fund Advisors LP lifted its position in Dianthus Therapeutics, Inc. (NASDAQ: DNTH) by 54.5% in the first quarter, according to its most recent filing with the Securities and Exchange…- benzinga.com Wedbush Maintains Outperform on Dianthus Therapeutics, Raises Price Target to $122 Wedbush analyst Laura Chico maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform and raises the price target from $105 to $122.
zacks.com Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Tops Revenue Estimates Dianthus Therapeutics, Inc. (DNTH) came out with a quarterly loss of $0.9 per share versus the Zacks Consensus Estimate of a loss of $0.93. This compares to a loss of $0.88 per share a year ago.
benzinga.com Dianthus Therapeutics Q2 EPS $(0.90) Misses $(0.88) Estimate, Sales $761.000K Beat $258.583K Estimate Dianthus Therapeutics (NASDAQ:DNTH) reported quarterly losses of $(0.90) per share which missed the analyst consensus estimate of $(0.88) by 2.27 percent. This is a 2.27 percent decrease over losses…
globenewswire.com Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 2026 Financial Results Advancing a neuromuscular franchise with claseprubart, a highly potent investigational classical pathway inhibitor, with best-in-disease potential across generalized Myasthenia Gravis (gMG), Chronic…
benzinga.com Dianthus Therapeutics Announces New Pipeline Candidate, DNTH312 for Autoimmune Disorders; The Company Expects DNTH312 to be Phase 1 Ready By End Of 2027 DNTH312 is an internally developed bifunctional fusion protein targeting potent inhibition of active C1s (aC1s) and BAFF/APRIL, two validated pathways with complementary disease modifying…
globenewswire.com Dianthus Therapeutics Announces DNTH312, a First-In-Class, Next-Generation Bifunctional Fusion Protein Combining Claseprubart and TACI, for Severe Autoimmune Diseases DNTH312 is an internally developed bifunctional fusion protein targeting potent inhibition of active C1s (aC1s) and BAFF/APRIL, two validated pathways with complementary disease modifying mechanisms…
globenewswire.com Dianthus Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4) NEW YORK and WALTHAM, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to…
benzinga.com Evercore ISI Group Maintains Outperform on Dianthus Therapeutics, Raises Price Target to $134 Evercore ISI Group analyst Gavin Clark-Gartner maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform and raises the price target from $120 to $134.
benzinga.com Why Is Dianthus Therapeutics Stock Trading Higher On Friday? Dianthus reports 75% responder rate for claseprubart in CIDP, while analysts say Sanofi's riliprubart faces rising risks after MOBILIZE.
benzinga.com Sanofi Trial Setback May Reinforce Argenx Vyvgart's Position In CIDP, Analyst Says Sanofi discontinues Phase 3 riliprubart study for CIDP due to low efficacy. SNY stock ticks up. Read the market & analyst reaction.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session - benzinga.com Wedbush Maintains Outperform on Dianthus Therapeutics, Raises Price Target to $105 Wedbush analyst Laura Chico maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform and raises the price target from $103 to $105.
- benzinga.com Dianthus Therapeutics Q1 EPS $(0.85) Beats $(1.07) Estimate, Sales $463.000K Beat $354.214K Estimate Dianthus Therapeutics (NASDAQ:DNTH) reported quarterly losses of $(0.85) per share which beat the analyst consensus estimate of $(1.07) by 20.56 percent. This is a 3.66 percent decrease over losses…
- benzinga.com Wolfe Research Initiates Coverage On Dianthus Therapeutics with Outperform Rating, Announces Price Target of $98 Wolfe Research analyst Andy Chen initiates coverage on Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform rating and announces Price Target of $98.
benzinga.com This Rocket Lab Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday Wall Street analysts changed outlook on top names. Clear Street initiated coverage on RKLB with Buy rating, $88 PT. See analyst ratings.- benzinga.com Wells Fargo Initiates Coverage On Dianthus Therapeutics with Overweight Rating, Announces Price Target of $135 Wells Fargo analyst Sadia Rahman initiates coverage on Dianthus Therapeutics (NASDAQ:DNTH) with a Overweight rating and announces Price Target of $135.
- benzinga.com Wedbush Maintains Outperform on Dianthus Therapeutics, Raises Price Target to $103 Wedbush analyst Laura Chico maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform and raises the price target from $80 to $103.
benzinga.com AutoZone To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Tuesday Analysts change outlook on top names: Truist cut KFY price target, Oppenheimer raised AZO target, B. Riley slashed YEXT target, Stifel cut MTN target, RBC raised KNTK target, Truist cut MAA target,…
benzinga.com This CrowdStrike Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday Wall Street analysts upgraded CRWD, ALEC, RIVN, SEDG, and DNTH. See what other analysts say about these stocks. Consider buying CRWD.- benzinga.com Wedbush Maintains Outperform on Dianthus Therapeutics, Raises Price Target to $80 Wedbush analyst Laura Chico maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform and raises the price target from $55 to $80.
- benzinga.com Raymond James Upgrades Dianthus Therapeutics to Strong Buy, Raises Price Target to $123 Raymond James analyst Steven Seedhouse upgrades Dianthus Therapeutics (NASDAQ:DNTH) from Outperform to Strong Buy and raises the price target from $63 to $123.
benzinga.com Baird Maintains Outperform on Dianthus Therapeutics, Raises Price Target to $132 Baird analyst Joel Beatty maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform and raises the price target from $67 to $132.- benzinga.com Clear Street Maintains Buy on Dianthus Therapeutics, Raises Price Target to $130 Clear Street analyst Bill Maughan maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Buy and raises the price target from $100 to $130.
- benzinga.com Dianthus Therapeutics Announces Proposed $400M Public Offering Dianthus announced that it has commenced an underwritten public offering of $400 million of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded…
- benzinga.com HC Wainwright & Co. Maintains Buy on Dianthus Therapeutics, Raises Price Target to $130 HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Buy and raises the price target from $47 to $130.